India, July 17 -- Intensity Therapeutics Inc. (INTS), a late-stage clinical biotechnology company, on Wednesday announced the resumption of the Phase 2 INVINCBLE-4 trial for INT230-6 in treating triple-negative breast cancer.
Triple negative breast cancer (TNBC) is an aggressive cancer with limited treatment options and poor long-term survival. Accounting for 11-17% of breast cancers, these malignancies test negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein.
The currently available treatments include systemic chemotherapy (anthracyclines, cyclophosphamide, paclitaxel, carboplatin) and the anti-PD-1 monoclonal antibody pembrolizumab. Immune checkpoint inhib...